Oncternal Therapeutics (NASDAQ:ONCT) Upgraded to “Buy” at Brookline Capital Management
Brookline Capital Management upgraded shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) from a hold rating to a buy rating in a report issued on Monday, Marketbeat.com reports. They currently have $2.00 price objective on the stock. Other research analysts have also recently issued research reports about the company. HC Wainwright upgraded Oncternal Therapeutics from […]
More Stories
AllianceBernstein Global High Income Fund (NYSE:AWF) Sees Significant Growth in Short Interest
AllianceBernstein Global High Income Fund (NYSE:AWF – Get Free Report) was the target of a large increase in short interest...
Clean TeQ (OTCMKTS:CTEQF) Trading 6.7% Higher – Time to Buy?
Clean TeQ Holdings Limited (OTCMKTS:CTEQF – Get Free Report) shares traded up 6.7% during mid-day trading on Monday . The...
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 1.7% – Should You Sell?
Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s share price was down 1.7% during mid-day trading on Monday . The...
AdvisorShares Vice ETF (NYSEARCA:VICE) Trading Up 0.8% – Here’s What Happened
AdvisorShares Vice ETF (NYSEARCA:VICE – Get Free Report)’s share price traded up 0.8% during trading on Monday . The company...
Helius Medical Technologies (NASDAQ:HSDT) Trading Up 4.8% – Time to Buy?
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Free Report)’s stock price traded up 4.8% during trading on Monday . The...
Short Interest in Maanshan Iron & Steel Company Limited (OTCMKTS:MAANF) Expands By 17,200.0%
Maanshan Iron & Steel Company Limited (OTCMKTS:MAANF – Get Free Report) was the recipient of a large growth in short...